Show simple item record

dc.contributor.authorPajuelo-Lozano, Natalia
dc.contributor.authorBargiela-Iparraguirre, Jone
dc.contributor.authorDomínguez Muñoz, Gemma 
dc.contributor.authorGómez Quiroga, Adoración 
dc.contributor.authorPerona, Rosario
dc.contributor.authorSánchez Pérez, María Isabel 
dc.contributor.otherUAM. Departamento de Bioquímicaes_ES
dc.contributor.otherUAM. Departamento de Medicinaes_ES
dc.contributor.otherUAM. Departamento de Química Inorgánicaes_ES
dc.contributor.otherInstituto de Investigaciones Biomédicas "Alberto Sols" (IIBM)es_ES
dc.date.accessioned2018-12-20T15:29:41Z
dc.date.available2018-12-20T15:29:41Z
dc.date.issued2018-10-17
dc.identifier.citationFrontiers in Pharmacology 9.OCT. (2018): 1197en_US
dc.identifier.issn1663-9812es_ES
dc.identifier.urihttp://hdl.handle.net/10486/686117
dc.description.abstractCisplatin is an election drug widely used in clinic for the treatment of advanced gastric cancer. However, the heterogeneity of the gastric tumors and its resistance to the drugs, make in some cases the response very low and the prognosis unpredictable. In this manuscript we aim to find the molecular processes involved in cisplatin-induced apoptosis in two gastric cancer cell lines with different sensitivity to the treatment: AGS and MKN45. The apoptosis induction is higher in MKN45 than in AGS cells in response to CDDP. The intrinsic apoptotic pathway study revealed that MKN45 cells undergo degradation of Mcl-1 together with an increase of Bid and Bad levels, which results in sensitivity to CDDP. In addition, DNA repair NER pathway is impair in MKN45 cells due to low levels of XPC and the absence of translocation of XPA and XPD to the nucleus after stimuli. Altogether, these results suggest that NER and Bcl-2 protein family proteins are potential targets to improve the response to cisplatin treatmenten_US
dc.description.sponsorshipThis work was supported by PI1401495 and P17-01401 (supported by FEDER funds) from Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain and by CTQ2015- 68779R. JB-I was supported by a fellowship from Catedra Isaac Costero, funded by Banco Santander-UAM and Beca Nacional de Posgrado CONACYT. NP-L was supported by a fellowship Programa de Formación de Profesorado Universitario REF: FPU15/04669, Ministerio de Educación, Cultura y Deporteen_US
dc.format.extent11 pag.es_ES
dc.format.mimetypeapplication/pdfen
dc.language.isospaen
dc.publisherFrontiers Media S.A.en_US
dc.relation.ispartofFrontiers in Pharmacologyen_US
dc.rightsCopyright © 2018 Pajuelo-Lozano, Bargiela-Iparraguirre, Dominguez, Quiroga, Perona and Sanchez-Perez.es_ES
dc.subject.otherApoptosisen_US
dc.subject.otherBcl-2 familyen_US
dc.subject.otherCisplatinen_US
dc.subject.otherGastric canceren_US
dc.subject.otherNER repairen_US
dc.titleXPA, XPC, and XPD modulate sensitivity in gastric cisplatin resistance cancer cellsen_US
dc.typearticleen
dc.subject.ecienciaMedicinaes_ES
dc.relation.publisherversionhttps://doi.org/10.3389/fphar.2018.01197es_ES
dc.identifier.doi10.3389/fphar.2018.01197es_ES
dc.identifier.publicationfirstpage1197-1es_ES
dc.identifier.publicationissueOCTOBERes_ES
dc.identifier.publicationlastpage1197-11es_ES
dc.identifier.publicationvolume9es_ES
dc.relation.projectIDGobierno de España. PI1401495es_ES
dc.relation.projectIDGobierno de España. P17-01401es_ES
dc.relation.projectIDGobierno de España. CTQ2015- 68779R.es_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionen
dc.rights.ccReconocimientoes_ES
dc.rights.accessRightsopenAccessen
dc.facultadUAMFacultad de Medicina
dc.institutoUAMInstituto de Investigaciones Biomédicas "Alberto Sols" (IIBM)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record